Table 8

Publications based on the BladderBaSe version 1.0

TitleJournal, yearConclusion
Improved long-term outcome of patients with non-muscle invasive, low and medium risk bladder cancer between 1997 and 2014; A Swedish Population-based Study.Scand J Urology, 2022Half of the patients had a recurrence. Rates were high in the first 2 years after diagnosis and very rare after 5 years of follow-up.
Rates decreased in the last time period studied. Mortality was mostly due to non-bladder cancer related disease. Grade was the most important prognosticator for long-term outcome.
Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancerScand J Urology, 2021Patients diagnosed with non-muscle-invasive bladder cancer when aged <50 are at decreased risk of bladder cancer-specific death when compared with their older (50-70) counterparts
Bladder cancer recurrence in papillary urothelial neoplasm of low malignant potential (PUNLMP) compared with G1 WHO 1999: a population-based studyScand J Urology, 2021The difference in risk of recurrence between primary stage TaG1 and PUNLMP stands in contrast to the recently adapted notion that treatment and follow-up strategies can be merged into one low-risk group of NMIBC.
Cumulative incidence of ureteroenteric strictures after radical cystectomy in a population-based Swedish cohort.Scand J Urology, 2021Ureteroenteric strictures requiring intervention may be more common than previously reported, affecting nearly one fifth of patients who have undergone RC for UBC. The annual incidence was highest in the first 2 years after surgery but the cumulative incidence increased continuously during 17 years of follow-up.
Survival after radical cystectomy during holiday periodsScand J Urology, 2021Same survival after radical cystectomy during holiday periods.
Cumulative incidence of midline incisional hernia and its surgical treatment after radical cystectomy and urinary diversion for bladder cancer: A nationwide population-based studyPloS One, 2021The cumulative incidence of midline incisional hernia (MIH) was 8% 3 years postoperatively, and increase over time. Avoiding postoperative wound dehiscence after midline closure is important to decrease the risk of MIH.
A Population-based Study on the Effect of a Routine Second-look Resection on Survival in Primary Stage T1 Bladder Cancer.Scand J Urology, 2021We found similar survival outcomes in patients with and patients without second-look Resection (SLR), but our study is likely affected by selection mechanisms. A randomised study defining the role of SLR in stage T1 BCa would be highly relevant to guide current praxis.
Thromboembolism in Muscle-Invasive Bladder Cancer. A Population-based Nationwide StudyBladder Cancer, 2021Cumulative incidence thromboembolism increased 2 years after diagnosis, and was commonly observed after 30 days from diagnosis and from first treatment date.
Treatment and prognosis of bladder cancer patients with other primary cancers. A nationwide population-based study in the BladderBaSeBJU International, 2020Other concomitant or previous primary cancers is common in bladder cancer patients, but carries just as high chance of treatment success as in patients with only bladder cancer.
A mediation analysis to explain socio-economic differences in bladder cancer survivalCancer Medicine, 2020Mediation analysis suggests that the association between socio-economic status (SES) and BC survival can be explained by several factors.
Radical cystectomy compared with intravesical BCG immunotherapy for high-risk NMIBC—is there a long-term survival difference? A Swedish nationwide analysisScand J Urology, 2019Improved cancer-specific survival after BCG compared with radical cystectomy in high-risk non-muscle invasive disease is probably related to selection mechanisms in the investigated population.
Sex Differences in Urothelial Bladder Cancer SurvivalClinical Genitourinary Cancer, 2020Excess bladder cancer mortality in females with muscle-invasive bladder cancer.
Period-specific mean annual hospital volume of radical cystectomy is associated with outcome and perioperative quality of care: a nationwide population-based studyBJU International, 2019With period-specific mean annual hospital volume (PSMAV) as a continuous variable, OS was improved for every increase of 10 RCs annually (HR 0.95, 95% CI 0.90 to 0.99). Moreover, higher PSMAV was associated with increased use of extended lymphadenectomy, continent reconstruction and use of neoadjuvant chemotherapy.
Management and outcome of muscle-invasive bladder cancer with clinical lymph node metastases. A nationwide population-based study in the BladderBaSeScand J Urology, 2019Decreased use of treatment with curative intent in patients with lymph node metastases, but among those receiving such treatment the combination of chemotherapy and cystectomy has increased during later years.
Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survivalScand J Urology, 2019Similar survival with or without neoadjuvant chemotherapy.
Management and outcome of TaG3 tumours of the urinary bladder in the nationwide, population-based bladder cancer database Sweden (BladderBaSe)Scand J Urology, 2019An underuse of adjuvant instillations in stage TaG3-disease was associated with decreased cancer-specific survival.
Survival after radiotherapy vs radical cystectomy for primary muscle-invasive bladder cancer: A Swedish nationwide population-based cohort studyCancer Medicine, 2019When taking into account unmeasured confounding by instrumental variable analysis, no differences in survival was found between the treatments for a selected group of patients.
A Nationwide, Population Based Analysis of Patients with Organ Confined, Muscle Invasive Bladder Cancer Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014Journal of Urology, 2019Patients not treated with curative intent are frequently hospitalised during their final year of life and primarily die of bladder cancer.
  • BladderBaSe, Bladder Cancer Data Base Sweden; NMIBC, non-muscle invasive bladder cancer.